| Rosuvastatin: a review of its effect on atherosclerosis. | |
| | |
MedLine Citation:
|
PMID: 18422395 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The HMG-CoA reductase inhibitor (statin) rosuvastatin (Crestor) is widely available for use in the management of dyslipidemia, and was recently approved in the US to slow the progression of atherosclerosis as part of a strategy to lower low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) to target levels. Rosuvastatin has greater lipid-lowering efficacy than any of the other currently available statins, and significantly more patients receiving rosuvastatin than other statins achieve LDL-C goals. Rosuvastatin delayed the progression of carotid atherosclerosis in patients with subclinical carotid atherosclerosis, moderately elevated cholesterol levels, and a low risk of cardiovascular disease in a primary prevention trial (METEOR). The results of METEOR suggest a possible role for the earlier use of rosuvastatin in primary prevention, although more data are needed from trials examining the effects of the drug on cardiovascular endpoints. Significant regression of atherosclerosis was seen with rosuvastatin 40 mg/day in patients with established coronary heart disease (CHD) in the ASTEROID trial, supporting the use of intensive lipid lowering in secondary prevention patients (although it should be noted that it has not yet been established that atherosclerotic regression translates into improved cardiovascular outcomes). Rosuvastatin is generally well tolerated, with a similar tolerability profile to that of other currently available statins. Thus, rosuvastatin is an important lipid-lowering treatment option that has been shown to cause regression of atherosclerosis in secondary prevention patients, and has a potential future role in delaying atherosclerosis in primary prevention patients. |
| | |
Authors:
|
Gillian M Keating; Dean M Robinson |
Related Documents
:
|
22734885 - Transporter function and cyclic amp turnover in normal colonic mucosa from patients wit... 22878665 - Loss of perivascular kir4.1 potassium channels in the sclerotic hippocampus of patients... 22767485 - Association of periodontitis with increased colonization by prevotella nigrescens. 22175725 - Treatment of patients with traumatic subdural effusion and concomitant hydrocephalus. 10555945 - Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset o... 8708165 - Increased oxygen consumption after cardiac surgery is associated with the inflammatory ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of cardiovascular drugs : drugs, devices, and other interventions Volume: 8 ISSN: 1175-3277 ISO Abbreviation: Am J Cardiovasc Drugs Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-04-21 Completed Date: 2008-09-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100967755 Medline TA: Am J Cardiovasc Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 127-46 Citation Subset: IM |
Affiliation:
|
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Atherosclerosis
/
prevention & control* Clinical Trials as Topic Fluorobenzenes / administration & dosage*, adverse effects, pharmacokinetics Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*, adverse effects, pharmacokinetics Pyrimidines / administration & dosage*, adverse effects, pharmacokinetics Sulfonamides / administration & dosage*, adverse effects, pharmacokinetics |
| Chemical | |
Reg. No./Substance:
|
0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Next Document: A multisite study of the capacity of acute stress disorder diagnosis to predict posttraumatic stress...